Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

EP: 1.Introduction and HR+/HER2– eBC Overview

EP: 2.Approaches to eBC Diagnosis and Risk Stratification

EP: 3.CDK4/6 Inhibitors Treatment Options in the eBC Setting

EP: 4.Clinical Trial Considerations for eBC Treatment Selection

EP: 5.Clinical Decision-Making for a Patient With eBC: Scenario and Strategies

Now Viewing

EP: 6.Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

Video content above is prompted by the following:

1. What adverse events (AEs) do you commonly see in your practice with CDK4/6 inhibitors?
   1. In your experience, how can these vary based on the treatment and patient population?
   2. What strategies work best for you to mitigate these toxicities?
   3. What dosing adjustments or lab monitoring can help manage toxicity for treatment continuation?
2. What is your approach to dose reductions or interruptions with CDK4/6 inhibitors when managing AEs? What is your threshold for dose reductions?
   1. How important is treatment adherence and continuation for maintaining the efficacy benefits?
   2. What strategies might promote adherence?
3. Could you walk through your approach to educating patients about potential CDK4/6 inhibitor toxicity?
   1. How do you counsel patients on symptom reporting?
4. How do you balance efficacy, quality of life, and adverse effect risks when selecting systemic therapy for patients with eBC?
   1. Does this balance shift for high-risk patients with no or low nodal involvement?